Viscous Fluticasone in Eosinophilic Esophagitis: a Suitable Step Forward |Biomedgrid

Eosinophilic esophagitis (EoE) is a chronic immune mediated disease of the esophagus whose incidence has risen rapidly and is now the first cause of dysphagia in the adult population. Symptoms significantly impact on quality of life and the chronic inflammation, if left untreated, can lead to fibrosis and strictures. Fluticasone propionate (FP) and budesonide (BUD), currently represent one of the first-line therapy for EoE and their efficacy has been demonstrated in multiple studies. However, no current FDA-approved medications exist in the United States, while an orodispersible budesonide tablet was officially approved in Europe but is still unavailable in many Countries.